Blanca Ledezma MSN, NP
Nurse Practitioner, UCLA Santa Monica Hematology/Oncology
Product Theater 2 | A CDK 4 & 6 Inhibitor with Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely to Do Worse (non-CE) Presentation by Lilly Oncology
Industry Sponsored Session | Insights on Bone Complications* from Solid Tumor Bone Metastases and Multiple Myeloma (non-CE) Presentation by Amgen
Industry Sponsored Session |Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings Presented by Lilly PP-AL-US-2989 © LillyUSA, LLC 2021. All rights reserved.
© 2022 Digitell, Inc. All Rights Reserved